Aura Biosciences (AURA) Stock Price, News & Analysis

Company Overview

Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision oncology treatments that selectively target and destroy cancer cells while preserving healthy tissue. The company’s technology platform uses virus-like drug conjugates (VDCs) designed to bind to specific markers on tumor cells, deliver a therapeutic payload, and stimulate an immune response against the cancer.

Aura’s lead product candidate is belzupacap sarotalocan, also known as bel-sar or AU-011. The investigational therapy is being developed as a localized treatment for primary choroidal melanoma, a form of eye cancer. Bel-sar is administered directly into the eye and activated with near-infrared laser light, with the goal of destroying tumor cells and promoting an immune-mediated response. Aura is also evaluating additional applications of its VDC platform in other solid tumors.

Founded in 2009, Aura Biosciences is headquartered in Lexington, Massachusetts. The company is led by Chief Executive Officer Elisabet de los Pinos, Ph.D., and is advancing its programs through clinical development and research collaborations. Its primary focus remains developing targeted therapies for cancers that have limited treatment options, beginning with ocular oncology.

Key Stats

• Today's Range: $6.61 to $7.11
• 50-Day Range: $6.82 to $8.16
• 52-Week Range: $4.73 to $9.53
• Volume: 259,141 shs
• Average Volume: 482,521 shs
• Market Capitalization: $697.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.50
• Consensus Rating: Hold

Aura Biosciences Stock Analysis - MarketRank™

Aura Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 576th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Aura Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aura Biosciences has a consensus price target of $17.50, representing about 160.2% upside from its current price of $6.73.

Amount of Analyst Coverage

Aura Biosciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aura Biosciences are expected to grow in the coming year, from ($1.61) to ($1.39) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aura Biosciences is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aura Biosciences is -3.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aura Biosciences has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.10% of the float of Aura Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Aura Biosciences has a short interest ratio ("days to cover") of 6.38.

Change versus previous month

Short interest in Aura Biosciences has recently increased by 0.72%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aura Biosciences does not currently pay a dividend.

Dividend Growth

Aura Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: N/A

News Sentiment

Aura Biosciences has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Aura Biosciences this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for AURA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Aura Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,330.00 in company stock.

Percentage Held by Insiders

1.90% of the stock of Aura Biosciences is held by insiders.

Percentage Held by Institutions

96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/15/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/16/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:AURA
• CIK: 1501796
• Web: www.aurabiosciences.com
• Phone: 617-500-8864
• Fax: N/A
• Employees: 113
• Year Founded: 2009

Price Target and Rating

• Average Price Target for Aura Biosciences: $17.50
• High Price Target: $18.00
• Low Price Target: $17.00
• Potential Upside/Downside: +160.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$106.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.18%
• Return on Assets: -62.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.82
• Quick Ratio: 16.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.16 per share
• Price / Book: 3.11

Miscellaneous

• Outstanding Shares: 103,705,000
• Free Float: 101,735,000
• Market Cap: $697.42 million
• Optionable: Not Optionable
• Beta: 0.40